Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737031 · ClinicalTrials.gov registry record · NA
Improving Tobacco Treatment Rates for Outpatient Cancer Patients Who Smoke
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 2,146
- Enrollment target
NCT04737031: Completed NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04737031 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2,146 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04737031, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,146 participants
- Enrollment target
Study Summary
The main purpose of this research study is to evaluate the effectiveness of "nudges" to clinicians, to patients, or to both in increasing Tobacco Use Treatment Service (TUTS) referral and engagement; and to explore clinician, patient, inner setting (e.g., clinic), and outer setting (e.g., payment structures) mechanisms related to TUTS referral and engagement. The investigators will employ rapid-cycle approaches to optimize the framing of nudges to clinicians and patients prior to initiating the trial and mixed methods to explore contextual factors and mechanisms. The investigators will conduct a four-arm pragmatic cluster randomize clinical trial to test the effectiveness of nudges to clinicians, nudges to patients, or nudges to both in increasing TUTS referral and engagement in cancer patients who smoke, vs. usual care (UC). The investigators hypothesize that each of the implementation strategy arms will significantly increase TUTS referral and engagement compared to UC and that the combination of nudges to clinicians and to patients will be the most effective.
Primary Outcome
Defined as the proportion of patients who received either a treatment referral (via the BPA or elsewhere in the EHR workflow) or a prescription for tobacco treatment medication (i.e., nicotine replacement, varenicline, or bupropion) Based on workflow issues and recommendations from the trial's Data and Safety Monitoring Board (DSMB), the primary outcome for this trial was adjusted to contain both referrals to TUTS and medication prescriptions.
Interventions
- OTHER Clinician Nudge
- OTHER Patient Nudge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,146 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
What the finished NCT04737031 record still lists
NCT04737031 is an interventional study that assigns participants to a tested intervention. Its 2,146 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which Clinician Nudge is the first listed.
NCT04737031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04737031 about?
NCT04737031 is a clinical study titled "Improving Tobacco Treatment Rates for Outpatient Cancer Patients Who Smoke". The main purpose of this research study is to evaluate the effectiveness of "nudges" to clinicians, to patients, or to both in increasing Tobacco Use Treatment Service (TUTS) referral and engagement; and to explore clinician, patient, inner setting (e.g., clinic), and outer setting (e.g., payment st...
What is the current status of trial NCT04737031?
This trial is currently completed. It is a NA study. The enrollment target is 2,146 participants. The study started on 2021-05-18. Estimated completion is 2022-07-31.
What interventions are being tested in trial NCT04737031?
The interventions under investigation include: Clinician Nudge (OTHER), Patient Nudge (OTHER).
Who is sponsoring clinical trial NCT04737031?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04737031's enrollment target sits among peer trials
2,146 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI